In vivo purging and relapse prevention following asct

Bone Marrow Transplantation

Volumn 29, Issue , 2002, Pages S5-S9

  Gisselbrecht, C ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Bcl 2; In vivo purging; Non Hodgkin s lymphoma; Rituximab; Stem cell transplantation

Indexed keywords

MONOCLONAL ANTIBODY; RITUXIMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CD34 ANTIGEN; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; METHOTREXATE; PROTEIN BCL 2;

AUTOTRANSPLANTATION; BONE MARROW PURGING; HUMAN; METHODOLOGY; NONHODGKIN LYMPHOMA; RECURRENT DISEASE; REVIEW; STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL FUNCTION; CHEMOSENSITIVITY; CLINICAL PROTOCOL; CONTAMINATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN CELL; IN VIVO STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; STEM CELL MOBILIZATION; STEM CELL PURGING; TREATMENT OUTCOME; TUMOR CELL; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; BONE MARROW PURGING; HUMANS; LYMPHOMA, NON-HODGKIN; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; HUMAN;

EID: 0036184696     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703295     Document Type: Article

References (33)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med 1995; 333: 1540–1545.
2. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262.
3. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 445–450.
4. Jacquy C, Soree A, Lambert F et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000; 110: 631–637.
5. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin’s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275–3280.
6. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457.
7. Freedman AS, Neuberg D, Mauch P et al. Long-term followup of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.
8. Yerly-Motta V, Racadot E, Fest T et al. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells. Leuk Lymphoma 1996; 23: 313–321.
9. Martin-Henao GA, Picon M, Limon A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Bone Marrow Transplant 1999; 23: 579–587.
10. Fouillard L, Laporte JP, Labopin M et al. Autologous stemcell transplantation for non-Hodgkin’s lymphomas: the role of graft purging and radiotherapy posttransplantation – results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803–2816.
11. Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems. Stem Cells 1997; 15: 297–304.
12. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin’s lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454–2464.
13. Schouten HC, Kvaloy S, Sydes M et al. The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2000; 11 (Suppl. 1): 91–94.
14. Bensinger WI. Should we purge? Bone Marrow Transplant 1998; 21: 113–115.
15. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.
16. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
17. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106.
18. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276.
19. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 200; 19: 389–397.
20. Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000; 96 (Suppl. 1): 950a.
21. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445.
22. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–1652.
23. Demidem A, Hanna N, Hariharan H et al. Chimeric anti-CD20 antibody (IDEC C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins. FASEB J 1995; 9: A206.
24. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDECC2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186.
25. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997; 10: 3266–3274.
26. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin’s lymphoma. Semin Oncol 1999; 5 (Suppl. 14): 115–122.
27. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts). Blood 1999; 94 (Suppl. 1): 141a.
28. Haioun C, Delfau-Larue MH, Beaujean F et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin’s lymphomas (NHL). A single institution study. Blood 2000; 96 (Suppl. 1): 384a.
29. Goldberg SL, Pecora AL, Jennis AA et al. Rituximab permits in vivo purging and collection of tumor-free stem cells prior to autologous transplantation for B-cell non-Hodgkin’s lymphoma. Blood 1999; 94 (Suppl. 1): 141a.
30. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.
31. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol 2000; 109: 729–735.
32. Horwitz SM, Breslin S, Negrin RS et al. Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications. Blood 2000; 96: 385a.
33. Buckstein R, Imrie K, Spaner D et al. Consolidative immunotherapy with rituxan in autologous stem cell transplantation in follicular lymphoma is associated with molecular remissions. Proc Am Soc Clin Oncol 2000; 19: 26a.